Jnj news releases. 96 per share compared to the previous rate of $4.

Jnj news releases – May 1, 2024 – Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC (“LLT”), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of daratumumab. JNJ Latest Press Releases -- November 22, 2024 -- Johnson & Johnson seeks U. With a 5. 1 Subsequent to the quarter. (July 20, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. m. (Eastern Time) on Tuesday, October 15 th to review third-quarter results. P. Presentations BEERSE, BELGIUM (21 January 2025) - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Marketing Authorisation (MA) for LAZCLUZE ® (lazertinib), in combination with RYBREVANT ® (amivantamab), for the first-line treatment of adult patients with advanced non This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward Johnson Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U. (Eastern Time). Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. The planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients Find press contacts, social media outlets, and other media related materials, including press releases, for Johnson & Johnson Vision. A JACKSONVILLE, FL – September 30, 2024 – Johnson & Johnson §, a global leader in eye health, has announced it’s expanding the roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC - IOL), TECNIS Odyssey, in the U. Copies of these filings are available online at www. – December 22, 2022 – Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, This press release contains forward-looking statements regarding the acquisition of Abiomed, Inc. At the new rate, the indicated dividend on an annual basis is $4. Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis Press Release. , a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as Stay up to date with all latest press releases from Johnson & Johnson (JNJ). [16] Johnson & Johnson. The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable RARITAN, N. — August 20, 2024 – Johnson & Johnson 1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd. , February 20, 2024 – Johnson & Johnson announced today that the U. Explore all Johnson & Johnson press releases published about about the company by date You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Get the latest Johnson & Johnson (JNJ) stock news and headlines to help you in your trading and investing decisions. The VARIPULSE™ Platform is designed to enable AFib treatment with a single device At Johnson & Johnson, we believe health is everything. These statements are based on current expectations of future events. Food and Drug Administration (FDA). Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren’s disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding JNJ-2113. More information can be found in Kenvue’s press release. Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech: Press Release. Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future NEW BRUNSWICK, NJ (March 7, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc. 00 per share in cash, corresponding Risk Factors,” in Johnson & Johnson’s most recently filed Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 1, 2024, in Johnson & Johnson’s subsequent filings with the SEC and in Shockwave’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 26, Acquisition strengthens Johnson Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics Johnson Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc. com for a complete list of currently planned earnings webcast/conference calls. Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact from the recent acquisition of V Johnson & Johnson reports sales growth, earnings growth and guidance for 2024. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Danvers, Mass. J. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of New Brunswick, NJ (January 2, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1. 1 Subsequent to the quarter Full-Year 2024 Guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and Press Release Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot Press Release Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech Press Release 1 Subsequent to the quarter Full-Year 2024 Guidance: Johnson & Johnson does not This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding icotrokinra (JNJ-2113). A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA ® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). (Eastern Time). Beerse, Belgium (October 28, 2024) – Johnson & Johnson today announced that the European Commission (EC) has approved EDURANT ® (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class and with a viral load ≤ Press Release. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PRNewswire 8:00 AM Find Johnson & Johnson (JNJ) news, corporate events, press releases, latest company updates and headlines ATLANTA, Ga. , October 1, 2020-- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. The Phase 3 study met its co-primary endpoints of Press Release: Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024: Press Release: 1 Subsequent to the quarter. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of ibrutinib. The reader is cautioned not to rely on these forward New Brunswick, N. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with Press Release. About Johnson & Johnson Titusville, N. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PRNewswire 8:00 AM-- November 19, 2024 -- RARITAN, N. Food and Drug Administration (FDA) for approval of a new indication for DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of New Brunswick, N. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product The press release will be available at approximately 6:45 a. Please note the fourth-quarter date of Wednesday, January 22 nd, 2025. jnj. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly New Brunswick, NJ – December 5, 2024 – Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today joined leading surgeons from around the world to initiate a standardized classification system for the global evaluation and reporting of surgical site outcomes (SSOs). Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p. The This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of amivantamab or lazertinib. The new corporate brand comes to life through a compelling (press release) Johnson & Johnson Statement on War in Ukraine (press release) 1 Subsequent to the quarter. for approximately $3. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 Auris Health’s Robotic Platform Expands Johnson & Johnson’s Digital Surgery Portfolio . 19 Johnson & Johnson. Johnson & Johnson Completes Acquisition of Shockwave Medical Press Release. Latest news and press releases on Johnson & Johnson’s efforts to stem the COVID-19 pandemic. s Newest Oldest . TREMFYA ® is the first and only approved Spring House, Pennsylvania , February 7, 2024 —Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for JNJ-2113. SAN FRANCISCO, Feb. NEW BRUNSWICK, N. Clinical and real-world data will highlight the Company’s differentiated Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent reduction in risk of disease progression or death1 New regimen reinforces daratumumab SC as a New Brunswick, N. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www. Press release. --(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc. Esketamine Receives Breakthrough Therapy Designation Johnson & Johnson (NYSE: JNJ) today announced an investment of more than $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. uncertainties and other factors can be found in Johnson & Johnson’s Annual NEW BRUNSWICK, NJ (January 8, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc. OMNY This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding SIMPONI uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Please refer to www. This press release contains “forward-looking statements” as defined SAN DIEGO, CA (December 8, 2024) – Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. 2% increase in the quarterly dividend, from $1. – October 10, 2024 – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLT™ Variable Angle Optimized Locking Technology Plating System launch. ) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a. 2 IL-23 plays a critical role in pathogenic This free app is available in the iTunes® store and includes stock information, news releases, company information, webcasts, SEC filings, the company’s pharmaceutical product pipeline and Annual Reports, among other information. 3%* Company is increasing 2023 full-year guidance midpoints for This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. 5 billion. Janssen Enters Into This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding JNJ-2113. 5 billion, J&J continues to outperform Wall Street's Palm Beach Gardens, FL, August 2, 2024 – Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, is launching a proprietary dual-use robotics and standalone navigation platform developed in collaboration with eCential Robotics. 8% to $21. Global Public NEW BRUNSWICK, NJ (May 16, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc. Janssen Enters Into Worldwide NEW BRUNSWICK, NJ (May 28, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire from Numab’s shareholders its wholly-owned subsidiary for the global rights to a novel, Johnson Johnson (NYSE: JNJ) today announced that the U. 24 per share on the company’s common stock. S. Skip to content the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Beerse, Belgium, (April 29, 2024) – Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for SIRTURO® (bedaquiline) and the conversion of the medicine’s Conditional Marketing Authorisation into a standard Marketing Authorisation. These statements are based on NEW BRUNSWICK, NJ (December 26, 2024) – Johnson & Johnson 1 (NYSE: JNJ) announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical. Nipocalimab has demonstrated clinical effect in four autoantibody-driven (press release) Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response (press release) Johnson & Johnson Consumer Inc. , July 29 th, 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Helathcare Conference on Thursday, September 5 th, at the Encore Boston Harbor, Everett, MA. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) to fully and finally resolve all current and future claims related to New Brunswick, N. Our Credo; Our Leadership; Code of Business Conduct; Corporate reports; Diversity, Equity & Inclusion; ESG Policies & Positions 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare NEW BRUNSWICK, N. 66 increasing by 19. The new full visual range IOL* 1 offers patients unmatched continuous full range of vision ‖¶¶6, so they can This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT® (amivantamab-vmjw) and lazertinib. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration, will represent the Company in a session scheduled at 10:55 a. (NYSE: KVUE) (“Kenvue”) announced today that it will begin trading today on the New York Stock Exchange under the ticker symbol “KVUE” in connection with its initial public offering (“IPO”). 24 per share, marking the 62 nd year of consecutive increases. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation (AFib). This press release contains “forward-looking statements” as defined in the Private Securities Litigation New Brunswick, NJ (April 16, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of NEW BRUNSWICK, N. FULL-YEAR 2022 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate Raritan, N. 5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma (RRMM) who have This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits of esketamine. , a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery This press release contains “forward This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of ERLEADA Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Spring House, Pa. Contact us with any questions or search this site for more information. and Danvers, Mass. We are building a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal. This press release contains "forward-looking statements" as defined in the Private Securities Litigation This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. New Brunswick, N. , November 1, 2022 – Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a. 20, 2024 – Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case today in the U. , a clinical-stage biopharmaceutical company with a The Company is licensing a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune and allergic diseases The agreement bolsters Johnson & Johnson’s commitment to addressing disease-relevant pathways across patient types through novel mechanisms and modalities to transform About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. The new facility will expand production of the Company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of DARZALEX FASPRO Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and New Brunswick, N. Food and Drug Administration (FDA) has issued traditional approval for SIRTURO ® (bedaquiline) as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least HORSHAM, Pa. Johnson & Johnson gains an NEW BRUNSWICK, N. 96 per share compared to the previous rate of $4. 4 Billion with operational growth of 6. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335. — October 9, 2024 — Johnson & Johnson 1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd. “We believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to address the unmet needs of the millions of patients each year who receive radiotherapy as part of their treatment,” said Laurent Levy, Nanobiotix Chief Executive HORSHAM, Pa. Morgan Healthcare Conference on Monday, January 13 th, at the Westin St. , December 12 th, 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the 43 rd Annual J. , November 29, 2023 – Johnson & Johnson announced today that more than 85 presentations from the Company’s robust hematology portfolio and pipeline will be presented at the 65 th Annual American Society of Hematology (ASH) Annual Meeting in San Diego from December 9-12. investor. Johnson Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY ® (talquetamab-tgvs) with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA and JNJ-2113. , Dec. Proteologix’s portfolio The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health Johnson Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEAD a , a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthenia gravis (gMG). If underlying assumptions prove inaccurate or known or Press Release: Johnson & Johnson Completes Acquisition of Abiomed: Press Release: FULL-YEAR 2023 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition NEW BRUNSWICK, N. This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding JNJ-2113. com. , October 10 th, 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18 th, at the Lotte New York Palace in New York. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene Press Release. and SANTA CLARA, Calif. This new company was formed in connection with the strategic collaboration About Johnson & Johnson. Operational growth excluding COVID-19 Vaccine of 9. Topic f0 All Topics Employees Global Public Health Health and Wellness Innovation . Johnson & Johnson MedTech, the global leader in heart recovery, announced today that the U. This press release contains "forward-looking statements" as defined in the Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company Former President and CEO of CVS Health, Merlo Will Assume Board Leadership Role with the New Consumer Health Company and Support Preparations for the Planned Separation, Expected to Occur in 2023 Irvine, CA – October 30, 2024 – Today, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the enrollment completion of the pilot phase of the OMNY-AF clinical trial, a study which evaluates the investigational OMNYPULSE™ Platform in the treatment of symptomatic paroxysmal atrial fibrillation (AFib) in the United States and Australia. The Johnson & Johnson Family of Companies remains committed to the prevention and treatment of diabetes, and will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals, and Consumer businesses. Francis in San Francisco, CA. Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer. Press Release. Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot: Press Release. Janssen enters into worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, New Brunswick, N. TREMFYA ® is the first NEW BRUNSWICK, N. Search + View Filters. – Sept. 19 per share to $1. 9%*. The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable Press Release: Johnson & Johnson reports positive topline results for Nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD) Press Release: Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU: You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6. , an independent surgical solutions company, in collaboration with Verily Life Sciences LLC (formerly Google Life Sciences). The ex-dividend date is February 18, 2025. , or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug NEW BRUNSWICK, N. MemoryGel™ Enhance Breast Implant is the first and only implant line created specifically for women with larger breast cup sizes undergoing breast reconstruction and reconstruction revision ATHENA Study findings demonstrate the safety and efficacy of larger-volume silicone breast implants for patients with larger breasts who request postmastectomy, Press Releases. The reader is cautioned not to rely on these forward-looking statements. 1 JNJ-2113 is the first and only investigational targeted oral peptide inhibitor designed to block the IL-23 receptor. About Johnson & Johnson . (October 4, 2024) – Johnson & Johnson announced today it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years. launch of the Shockwave E 8 Peripheral IVL Catheter, following clearance by the U. gov, NEW BRUNSWICK, N. JNJ Latest Press Releases-- November 22, 2024 --Johnson & Johnson seeks U. (Eastern Time) the morning of the conference call. A replay and podcast will be available approximately two hours after the RARITAN, N. , or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), Irvine, CA – November 7, 2024 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U. Janssen Biotech, Inc. – December 12, 2024 – Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic shock. Explore all Johnson & Johnson published press releases by date and/or topic of news. Spring House, PA (November 11, 2024) – Johnson & Johnson today announced that the U. Latest news. , a privately-held company focused on developing innovative treatment options for patients with heart failure. 16 Johnson & Johnson. Johnson & Johnson Completes Acquisition of Ambrx Press Release. 5 with SmartAssist and Impella CP with View the latest Johnson & Johnson (JNJ) company-issued press releases. Food and Drug Administration (FDA) has approved TREMFYA ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. , August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. , December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy . Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. and Bedminster, N. The acquisition of V-Wave extends Johnson SANTA CLARA, CA, September 16, 2024 – Shockwave Medical, Inc. New Brunswick, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc. Do Not Sell or Share My Personal Information This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding icotrokinra (JNJ-2113). . (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of amivantamab or lazertinib. Risk Factors,” and in Johnson & Johnson’s subsequent The press release will be available at approximately 6:45 a. News from johnson & johnson A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, Find press contacts, social media outlets, and other media related materials, including press releases, for Johnson & Johnson Vision. 69 increasing 4. Innovation; Caring & giving; Personal stories; Health & wellness; Our Company. Johnson & Johnson's latest earnings reveal a company navigating both growth and legal hurdles. Food and Drug Administration (FDA) has expanded the indications for the Impella 5. , and/or Johnson & Johnson. FULL-YEAR 2022 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and SPRING HOUSE, PENNSYLVANIA, November 8, 2023 – Janssen Pharmaceuticals, Inc. Experts from across surgical specialties and healthcare disciplines aim to This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of DARZALEX FASPRO uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, Press Release: Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company: Press Release: 1 Subsequent to the quarter. 4 billion in cash. The system, called the VELYS™ Active Robotic-Assisted CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with Press releases; Menu. , January 13, 2025 – Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. 0%* Earnings per share (EPS) of $1. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, This press release contains “forward-looking statements” regarding the acquisition of Momenta. If underlying assumptions prove inaccurate or known or NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. The dividend is payable on March 4, 2025 to shareholders of record at the close of business on February 18, 2025. (February 5, 2024) – Johnson & Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2 DAHLIAS study of nipocalimab in adults with Sjögren’s disease (SjD). , entered into a definitive agreement to acquire Auris Health, Inc. Date f1 All Dates 2022 Past . Janssen Enters Into Worldwide NEW BRUNSWICK, NJ, June 21, 2024 (Business Wire) – Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc. Discover J&J. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1. 3% and adjusted EPS of $2. Johnson Johnson (NYSE:JNJ) announced today the submission of a supplemental Biologics License Application (sBLA) to the U. [21] Johnson & Johnson. , January 15, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TAR-200. The Shockwave E 8 catheter is designed to optimize the treatment of At Johnson & Johnson, we believe health is everything. 10, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the formation of Verb Surgical Inc. Johnson & Johnson Press Release. sec. 76 per share. , part of Johnson & Johnson MedTech* and a global leader in the field of circulatory restoration, announced the full U. Psychiatric and Mental Health Congress (Psych Congress), taking place October 29 to November 2 in Boston, Massachusetts. November 12, 2021– Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced its intent to separate the Company’s Consumer Health business, creating a new publicly traded company. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U. , April 5, 2024 – Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. Risk Factors,” and in Johnson & Johnson’s subsequent This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of cilta-cel. , Eastern Time. Food and Drug Administration (FDA) approved DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for New Brunswick, NJ (January 2, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Johnson Johnson (NYSE:JNJ) announced today that the U. Please note the first-quarter date of Tuesday, April 15 th, 2025. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. 4%* and adjusted operational growth of 4. , October 24, 2024 — Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U. This press release contains WEST CHESTER, Penn. uncertainties and other factors can be found in Johnson & Johnson’s Annual Beerse, Belgium (July 2, 2024) – Johnson & Johnson announced today that the U. Caring for the world, one person at a timeinspires and unites the people of Johnson & 2023 Third-Quarter reported sales growth of 6. This Raritan, N. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time). September 28, 2022 — Johnson & Johnson (the “Company”) (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the NEW BRUNSWICK, N. About Johnson & Johnson This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding SIMPONI uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. The innovative system represents an evolution in our fracture management solutions designed to improve stability, NEW BRUNSWICK, N. Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding icotrokinra (JNJ-2113). V-Wave will operate as part of Johnson & Johnson MedTech. See the financial results, regional and segment sales, and COVID-19 vaccine impact for Q4 Get the latest Johnson & Johnson (JNJ) stock news and headlines to help you in your trading and investing decisions. , JANUARY 19, 2024 – Johnson & Johnson announced today that the U. BEERSE, BELGIUM, 23 February 2024 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and Johnson & Johnson COVID-19 vaccine booster, after single dose primary regimen, provided rapid and robust increase in spike-binding antibodiesNew studies build on data demonstrating strong durability through eight months after immunization This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act NEW BRUNSWICK 4 May, 2023 – Kenvue Inc. This acquisition provides an opportunity for the RIO DE JANEIRO (September 27, 2024) – Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI ® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of NEW BRUNSWICK, N. This press release contains “forward-looking statements” as defined in the Private This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of amivantamab. Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 Press Release : 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this Get the latest Johnson & Johnson (JNJ) stock news and headlines to help you in your trading and investing decisions. January 28, 2021 (RARITAN, N. Full-Year 2024 Guidance: Latest news and press releases on Johnson & Johnson’s efforts to stem the COVID-19 pandemic. uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal Johnson Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). 2% sales increase, bringing in $22. , a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment. , a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA ® NEW BRUNSWICK, N. efxpj tojsb fgfkz ggrl tlhc tkygxt xruno typlf ibxdqa tqtfu